Clinical TrialApr 28, 2026, 09:04 AM
CELZ Ultrasome™ OA Study Hits Primary Endpoint; 93% Patient Improvement
AI Summary
Creative Medical Technology Holdings, Inc. (CELZ) announced breakthrough positive results from its pilot study of Ultrasome™, a cell-free regenerative therapy for knee osteoarthritis. The study achieved its primary endpoint, with an industry-leading 93% of patients showing clinically meaningful improvements in mobility and pain reduction, and no serious adverse events. Ultrasome™ is derived from the company's GMP-manufactured CELZ-201, expanding its platform into scalable, off-the-shelf therapies for the large, underserved osteoarthritis market. CELZ plans to expand clinical execution and evaluate strategic pathways toward commercialization and partnerships.
Key Highlights
- Ultrasome™ pilot study for knee OA achieved its primary endpoint.
- 93% of patients demonstrated clinically meaningful improvements in mobility and pain.
- The therapy was well-tolerated with no serious adverse events reported.
- Ultrasome™ is derived from GMP-manufactured CELZ-201 (Olastrocel).
- Osteoarthritis affects over 30 million US adults, representing a multi-billion-dollar market.
- Company plans to expand clinical execution and evaluate commercialization pathways.